---
title: 'Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in
  moderate-to-severe myasthenia gravis: A phase 2 randomized study'
date: '2023-11-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37988976/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231122170715&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Iscalimab showed favorable safety and improvements compared
  with placebo in non-thymectomized patients with moderate-to-severe MG. It did not
  show any protective effect in patients with moderate-to-severe ...'
disable_comments: true
---
CONCLUSION: Iscalimab showed favorable safety and improvements compared with placebo in non-thymectomized patients with moderate-to-severe MG. It did not show any protective effect in patients with moderate-to-severe ...